Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing ...
Recursion, one of the most buzzed-about startups using machine learning to speed up drug discovery trials, said Wednesday it raised $239 million in Series D led by pharmaceutical maker Bayer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results